Company Overview - Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers [2] - The company aims to "erase cancer" by creating novel therapies and combination regimens that comprehensively shut down the RAS/MAPK pathway [2] Upcoming Events - Management will participate in the Jefferies Global Healthcare Conference from June 3-5, 2025, with a fireside chat scheduled for June 4 at 5:30 pm Eastern Time [1] - The company will also attend the Goldman Sachs 46th Annual Global Healthcare Conference from June 9-11, 2025, with a fireside chat on June 10 at 2:40 pm Eastern Time [1] - Live audio webcasts of these events will be available on Erasca's website, with archived replays accessible for 30 days post-event [1]

Core Viewpoint - Aptose Biosciences Inc. is advancing its clinical-stage precision oncology therapy, tuspetinib (TUS), in a Phase 1/2 trial (TUSCANY) for newly diagnosed acute myeloid leukemia (AML) patients, with recent approval to escalate dosing based on positive safety and efficacy data [1][2][3]. Group 1: Clinical Trial Progress - The Cohort Safety Review Committee has approved the escalation of the TUS dose from 80 mg to 120 mg due to favorable safety and efficacy data [1][3]. - The first patient has been dosed at the 120 mg level, and enrollment for this cohort is ongoing [1][7]. - No significant safety concerns or dose-limiting toxicities have been reported in the trial, including no prolonged myelosuppression in subjects [2][7]. Group 2: Efficacy and Safety Data - Data from the initial cohorts (40 mg and 80 mg) show promising clinical safety and antileukemic activity, even in difficult-to-treat AML populations [3][4]. - The TUS+VEN+AZA triplet therapy has achieved complete remissions (CRs) and minimal residual disease (MRD) negativity with favorable safety profiles [7]. Group 3: Future Presentations and Data - Updated data will be presented at the European Hematology Association Congress (EHA 2025) in Milan, Italy, including safety, CRs, MRD, and pharmacokinetic findings [2][4]. - The TUSCANY trial is being conducted at 10 leading U.S. clinical sites, with an anticipated enrollment of 18-24 patients by mid-late 2025 [5].

Financial Data and Key Metrics Changes - The company recorded a net loss of approximately $4,500,000 for Q1 2025, down from $5,400,000 in the same period last year, reflecting improved operational efficiency [21][24] - General and administrative expenses were approximately $1,510,000 for Q1 2025, compared to $1,480,000 in the prior year [23] - R&D expenses decreased to approximately $3,300,000 in Q1 2025 from $4,300,000 in Q1 2024, primarily due to reduced costs in CRO and clinical site expenses [23] Business Line Data and Key Metrics Changes - The clinical pipeline includes significant advancements, particularly with LP-184, which is in a Phase 1a trial with enrollment expected to complete by June 2025 [7][10] - The HARMONIC Phase 2 trial for LP-300 is progressing well, with a reported 86% clinical benefit rate and 43% objective response rate in the safety lead-in cohort [11] Market Data and Key Metrics Changes - The estimated annual market potential for LP-184's target indications is approximately $14,000,000,000, with $4,000,000,000 for CNS cancers and about $10,000,000,000 for other solid tumors [13] - The market opportunity for metastatic triple negative breast cancer (TNBC) is estimated to exceed $4,000,000,000 annually [10] Company Strategy and Development Direction - The company is focused on leveraging AI and machine learning to enhance drug discovery and development processes, aiming to transform precision oncology therapies [5][6] - Plans to commercialize the RADAR AI platform through a freemium model to foster collaborations and enhance data aggregation [15][39] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of AI in drug development, emphasizing that the integration of agentic capabilities in the RADAR platform will drive significant advancements in therapeutic development [27][28] - The company is strategically positioned to maximize shareholder value through disciplined capital management and potential partnerships with biopharma companies [20][30] Other Important Information - The company ended the quarter with approximately $19,700,000 in cash, cash equivalents, and marketable securities, providing an expected operating runway through at least May 2026 [20][24] - The RADAR AI platform has expanded to approximately 200,000,000,000 oncology-focused data points, enhancing its capabilities for drug candidate optimization and biomarker development [13][14] Q&A Session Summary Question: Plans for commercializing AI modules - The company plans to start with a freemium model for the blood-brain barrier penetration module to encourage collaboration and data aggregation [37][39] Question: Clarification on the HARMONIC trial design - The expansion cohort will include both US and Asian patients, with a randomized design to ensure quality data [40][44] Question: Expectations for LP-184 trial enrollment - The trial is expected to be fully enrolled next month, with preliminary data anticipated shortly thereafter [48] Question: FDA's use of AI in evaluations - Management believes the FDA will increasingly utilize AI in its evaluations, which could improve efficiency and reduce costs [49][50] Question: Attracting new investors through AI initiatives - The company aims to attract new investors by opening up AI modules and demonstrating their precision and focus compared to existing tools [52]

Company Participation - Prelude Therapeutics will participate in the Citizens Life Sciences Conference in New York on May 7, 2025 [1] - The company's CEO, President and Chief Medical Officer, and Chief Scientific Officer will engage in a fireside chat during the conference [2] Company Overview - Prelude Therapeutics is a clinical-stage precision oncology company focused on developing innovative medicines for cancer patients with high unmet needs [3] - The company's pipeline includes first-in-class SMARCA2 degraders and a potentially best-in-class CDK9 inhibitor, along with next-generation degrader antibody conjugates [3] - Prelude aims to extend the promise of precision medicine to all cancer patients in need [3]

Company Participation - Prelude Therapeutics will participate in the Citizens Life Sciences Conference in New York on May 7, 2025 [1] - The participation will include a fireside chat featuring key executives: Kris Vaddi, Jane Huang, and Peggy Scherle [2] Company Overview - Prelude Therapeutics is a clinical-stage precision oncology company focused on developing innovative medicines for cancer patients with high unmet needs [3] - The company's pipeline includes first-in-class SMARCA2 degraders and a potentially best-in-class CDK9 inhibitor [3] - Prelude is also working on next-generation degrader antibody conjugates (Precision ADCs) in collaboration with partners [3]

Core Insights - Acrivon Therapeutics is hosting a virtual R&D event on March 25, 2025, to showcase its drug discovery capabilities and provide updates on its clinical studies [1][2] - The company utilizes its proprietary Acrivon Predictive Precision Proteomics (AP3) platform for developing precision oncology medicines tailored to patients' tumor sensitivities [3][4] Company Overview - Acrivon Therapeutics is a clinical stage biopharmaceutical company focused on precision oncology, employing the AP3 platform to discover and develop drug candidates [3] - The AP3 platform generates extensive quantitative data for pathway-based drug design and response prediction, facilitating rational drug discovery and the identification of effective drug combinations [3][4] Clinical Development - Acrivon's lead candidate, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2 trial for multiple tumor types [3] - ACR-368 has received Fast Track designation from the FDA for use as monotherapy in patients with platinum-resistant ovarian or endometrial cancer [3] - The company is also developing ACR-2316, a selective WEE1/PKMYT1 inhibitor, aimed at enhancing single-agent activity through the activation of key cell cycle proteins [4] Key Opinion Leaders - The event will feature presentations from notable experts in gynecologic oncology, including Dr. Mansoor Raza Mirza, Dr. Robert L. Coleman, and Dr. Jesper Olsen, who will discuss the implications of Acrivon's research [5]

As filed with the Securities and Exchange Commission on December 5, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Radiopharm Theranostics Limited (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Australia 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Lev ...